Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Ductal adenocarcinoma of the prostate: Clinical and biological profiles.

Vinceneux A, Bruyère F, Haillot O, Charles T, de la Taille A, Salomon L, Allory Y, Ouzaid I, Choudat L, Rouprêt M, Comperat E, Houede N, Beauval JB, Vourc'h P, Fromont G.

Prostate. 2017 Sep;77(12):1242-1250. doi: 10.1002/pros.23383. Epub 2017 Jul 12.

PMID:
28699202
2.

PTEN loss and ERG protein expression are infrequent in prostatic ductal adenocarcinomas and concurrent acinar carcinomas.

Morais CL, Herawi M, Toubaji A, Albadine R, Hicks J, Netto GJ, De Marzo AM, Epstein JI, Lotan TL.

Prostate. 2015 Oct;75(14):1610-9. doi: 10.1002/pros.23042. Epub 2015 Jul 14.

3.

Immunohistochemistry of ductal adenocarcinoma of the prostate and adenocarcinomas of non-prostatic origin: a comparative study.

Seipel AH, Samaratunga H, Delahunt B, Wiklund P, Clements M, Egevad L.

APMIS. 2016 Apr;124(4):263-70. doi: 10.1111/apm.12504. Epub 2016 Jan 17.

PMID:
26778368
4.

Genetic profile of ductal adenocarcinoma of the prostate.

Seipel AH, Whitington T, Delahunt B, Samaratunga H, Mayrhofer M, Wiklund P, Grönberg H, Lindberg J, Egevad L.

Hum Pathol. 2017 Nov;69:1-7. doi: 10.1016/j.humpath.2017.04.015. Epub 2017 Apr 27.

PMID:
28457729
5.

SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.

Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA.

Urol Oncol. 2016 May;34(5):235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22.

PMID:
26725250
6.

Cytoplasmic PTEN protein loss distinguishes intraductal carcinoma of the prostate from high-grade prostatic intraepithelial neoplasia.

Lotan TL, Gumuskaya B, Rahimi H, Hicks JL, Iwata T, Robinson BD, Epstein JI, De Marzo AM.

Mod Pathol. 2013 Apr;26(4):587-603. doi: 10.1038/modpathol.2012.201. Epub 2012 Dec 7.

7.

Evidence for molecular differences in prostate cancer between African American and Caucasian men.

Khani F, Mosquera JM, Park K, Blattner M, O'Reilly C, MacDonald TY, Chen Z, Srivastava A, Tewari AK, Barbieri CE, Rubin MA, Robinson BD.

Clin Cancer Res. 2014 Sep 15;20(18):4925-34. doi: 10.1158/1078-0432.CCR-13-2265. Epub 2014 Jul 23.

8.

Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.

Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Feng FY.

Eur Urol. 2015 Oct;68(4):555-67. doi: 10.1016/j.eururo.2015.04.033. Epub 2015 May 8.

9.

Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer.

Terry S, Nicolaiew N, Basset V, Semprez F, Soyeux P, Maillé P, Vacherot F, Ploussard G, Londoño-Vallejo A, de la Taille A, Allory Y.

Cancer. 2015 May 1;121(9):1422-30. doi: 10.1002/cncr.29233. Epub 2015 Jan 13.

10.

Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.

Kim SH, Kim SH, Joung JY, Lee GK, Hong EK, Kang KM, Yu A, Nam BH, Chung J, Seo HK, Park WS, Lee KH.

PLoS One. 2015 Apr 21;10(4):e0122498. doi: 10.1371/journal.pone.0122498. eCollection 2015.

11.

Immunohistochemical profile of ductal adenocarcinoma of the prostate.

Seipel AH, Samaratunga H, Delahunt B, Wiklund F, Wiklund P, Lindberg J, Grönberg H, Egevad L.

Virchows Arch. 2014 Nov;465(5):559-65. doi: 10.1007/s00428-014-1636-0. Epub 2014 Jul 25.

PMID:
25059847
12.

Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens.

Seipel AH, Wiklund F, Wiklund NP, Egevad L.

Virchows Arch. 2013 Apr;462(4):429-36. doi: 10.1007/s00428-013-1385-5. Epub 2013 Feb 27.

PMID:
23443941
13.

TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas.

Lotan TL, Toubaji A, Albadine R, Latour M, Herawi M, Meeker AK, DeMarzo AM, Platz EA, Epstein JI, Netto GJ.

Mod Pathol. 2009 Mar;22(3):359-65. doi: 10.1038/modpathol.2008.236. Epub 2009 Jan 16.

14.

Clinico-pathological significance of the molecular alterations of the SPOP gene in prostate cancer.

García-Flores M, Casanova-Salas I, Rubio-Briones J, Calatrava A, Domínguez-Escrig J, Rubio L, Ramírez-Backhaus M, Fernández-Serra A, García-Casado Z, López-Guerrero JA.

Eur J Cancer. 2014 Nov;50(17):2994-3002. doi: 10.1016/j.ejca.2014.08.009. Epub 2014 Sep 6.

PMID:
25204806
15.

Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.

Morais CL, Han JS, Gordetsky J, Nagar MS, Anderson AE, Lee S, Hicks JL, Zhou M, Magi-Galluzzi C, Shah RB, Epstein JI, De Marzo AM, Lotan TL.

Am J Surg Pathol. 2015 Feb;39(2):169-78. doi: 10.1097/PAS.0000000000000348.

16.

Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.

Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.

Genes Chromosomes Cancer. 2012 Aug;51(8):781-91. doi: 10.1002/gcc.21963. Epub 2012 Apr 16.

PMID:
22505341
17.

SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.

Grupp K, Diebel F, Sirma H, Simon R, Breitmeyer K, Steurer S, Hube-Magg C, Prien K, Pham T, Weigand P, Michl U, Heinzer H, Kluth M, Minner S, Tsourlakis MC, Izbicki JR, Sauter G, Schlomm T, Wilczak W.

Prostate. 2013 Nov;73(15):1690-8. doi: 10.1002/pros.22707. Epub 2013 Jul 10.

PMID:
23843146
18.

Improved differentiation between ductal and acinar prostate cancer using three-dimensional histology and biomarkers.

Tarján M, Chen HH, Tot T, Wu W, Lenngren A, Dean PB, Tabár L.

Scand J Urol Nephrol. 2012 Aug;46(4):258-66. doi: 10.3109/00365599.2012.675586. Epub 2012 Apr 23.

PMID:
22519924
19.

Diagnostic criteria for ductal adenocarcinoma of the prostate: interobserver variability among 20 expert uropathologists.

Seipel AH, Delahunt B, Samaratunga H, Amin M, Barton J, Berney DM, Billis A, Cheng L, Comperat E, Evans A, Fine SW, Grignon D, Humphrey PA, Magi-Galluzzi C, Montironi R, Sesterhenn I, Srigley JR, Trpkov K, van der Kwast T, Varma M, Zhou M, Ahmad A, Moss S, Egevad L.

Histopathology. 2014 Aug;65(2):216-27. doi: 10.1111/his.12382. Epub 2014 Apr 3.

PMID:
24467262
20.

ERG expression in mucinous prostatic adenocarcinoma and prostatic adenocarcinoma with mucinous features: comparison with conventional prostatic adenocarcinoma.

Johnson H, Zhou M, Osunkoya AO.

Hum Pathol. 2013 Oct;44(10):2241-6. doi: 10.1016/j.humpath.2013.05.006. Epub 2013 Jul 10.

PMID:
23849895

Supplemental Content

Support Center